France
Advanced BioDesign is a French clinical stage company, founded in 2010, with a focus on developing a novel therapy to address the high unmet medical needs in cancer treatment. The company's approach involves the selective inhibition of ALDH enzymes, which play a crucial role in the detoxification mechanism of cancer cells, enabling them to evade programmed cell death. With its promising therapeutic approach, Advanced BioDesign has garnered significant attention from investors, most recently securing a €14.30M Venture Round investment on 02 February 2023 from Xerys Capital.
The company operates within the Biopharma, Biotechnology, Health Care, and Health and Wellness sectors. Its focused efforts on overcoming tumor drug resistance align with the growing demand for innovative solutions in cancer therapeutics. With demonstrated potential in addressing a critical aspect of cancer biology, Advanced BioDesign presents an intriguing investment opportunity in the rapidly evolving biopharmaceutical landscape.
